Lidija Bošković1, Maja Gašparić2, Marija Petković3, Damir Gugić4, Ingrid Belac Lovasić5, Željko Soldić6, Branka Petrić Miše7, Nina Dabelić8, Ljubica Vazdar9, Eduard Vrdoljak10. 1. Clinic for Oncology and Radiotherapy, University Hospital Split, Spinčićeva 1, HR-21000 Split, Croatia. Electronic address: lidija.boskovic123@gmail.com. 2. PLIVA Croatia Ltd., Prilaz baruna Filipovića 25, HR-10000 Zagreb, Croatia. Electronic address: maja.gasparic@pliva.com. 3. Clinic for Oncology and Radiotherapy, University Hospital Rijeka, Krešimirova 42, HR-51000 Rijeka, Croatia. Electronic address: marija.petkovic@ri.t-com.hr. 4. Clinic for Oncology and Radiotherapy, University Hospital Osijek, Huttlerova 4, HR-31000 Osijek, Croatia. Electronic address: damir.gugic7@gmail.com. 5. Clinic for Oncology and Radiotherapy, University Hospital Rijeka, Krešimirova 42, HR-51000 Rijeka, Croatia. Electronic address: ingrid.belac@ri.t-com.hr. 6. Clinic for Oncology and Nuclear Medicine, University Hospital Sestre Milosrdnice, Vinogradska cesta 29, HR-10000 Zagreb, Croatia. Electronic address: zeljko.soldic@kbcsm.hr. 7. Clinic for Oncology and Radiotherapy, University Hospital Split, Spinčićeva 1, HR-21000 Split, Croatia. Electronic address: brapemi@gmail.com. 8. Clinic for Oncology and Nuclear Medicine, University Hospital Sestre Milosrdnice, Vinogradska cesta 29, HR-10000 Zagreb, Croatia. Electronic address: nina.dabelic@kbcsm.hr. 9. Clinic for Tumors, University Hospital Sestre Milosrdnice, Ilica 197, HR-10 000 Zagreb, Croatia. Electronic address: ljubica.vazdar@gmail.com. 10. Clinic for Oncology and Radiotherapy, University Hospital Split, Spinčićeva 1, HR-21000 Split, Croatia. Electronic address: edo.vrdoljak@gmail.com.
Abstract
OBJECTIVES: Randomized trials involving aromatase inhibitors (AIs) in the adjuvant treatment of breast cancer patients have reported increased osteoporosis risk. Bone loss can be reduced with appropriate life style, vitamin D and calcium supplements, and with bisphosphonate therapy. The aim of this analysis was to investigate adherence to vitamin D and calcium in postmenopausal breast cancer patients receiving adjuvant non-steroidal AIs, and oncologists' adherence to the bone health guidelines. MATERIAL AND METHODS: This prospective study included 438 newly diagnosed patients and those who have already been receiving non-steroidal AIs for up to 3.5 years. Median endocrine therapy duration before recruitment in the study was 10.5 months (interquartile 4.8-26.6). RESULTS: Densitometry was performed on 142 patients (32.4%) before initiation of endocrine therapy, and on additional 38 (8.6%) patients at second study visit. Densitometry was not performed on 258 (59%) patients. Vitamin D and calcium were prescribed to 329/438 (75.1%) patients at some point during the study. Patients who took more than 80% of the prescribed dose were considered adherent. Self-reported adherence was 88.4%. Osteoporosis was diagnosed in 24 patients (5.5%) of the total study population, bearing in mind that 258/438 (59%) patients did not have densitometry. Bisphosphonates were prescribed to 54/438 (12.3%) patients, whilst only 19 (35.2%) of those had osteoporosis. CONCLUSION: In this analysis, lack of oncologists' adherence to the bone health guidelines was observed. In addition, a significant proportion of the patients did not adhere to the vitamin D and calcium.
OBJECTIVES: Randomized trials involving aromatase inhibitors (AIs) in the adjuvant treatment of breast cancerpatients have reported increased osteoporosis risk. Bone loss can be reduced with appropriate life style, vitamin D and calcium supplements, and with bisphosphonate therapy. The aim of this analysis was to investigate adherence to vitamin D and calcium in postmenopausal breast cancerpatients receiving adjuvant non-steroidal AIs, and oncologists' adherence to the bone health guidelines. MATERIAL AND METHODS: This prospective study included 438 newly diagnosed patients and those who have already been receiving non-steroidal AIs for up to 3.5 years. Median endocrine therapy duration before recruitment in the study was 10.5 months (interquartile 4.8-26.6). RESULTS: Densitometry was performed on 142 patients (32.4%) before initiation of endocrine therapy, and on additional 38 (8.6%) patients at second study visit. Densitometry was not performed on 258 (59%) patients. Vitamin D and calcium were prescribed to 329/438 (75.1%) patients at some point during the study. Patients who took more than 80% of the prescribed dose were considered adherent. Self-reported adherence was 88.4%. Osteoporosis was diagnosed in 24 patients (5.5%) of the total study population, bearing in mind that 258/438 (59%) patients did not have densitometry. Bisphosphonates were prescribed to 54/438 (12.3%) patients, whilst only 19 (35.2%) of those had osteoporosis. CONCLUSION: In this analysis, lack of oncologists' adherence to the bone health guidelines was observed. In addition, a significant proportion of the patients did not adhere to the vitamin D and calcium.
Authors: Evelyne Bischof; Fabienne D Schwab; Elena Laura Georgescu Margarint; Céline Montavon; Iris Zünti; Anna Schollbach; Andreas Schötzau; Anna Hirschmann; Julia Landin; Christian Meier; Kurzeder Christian; Marcus Vetter Journal: Bone Rep Date: 2021-12-11
Authors: Ena Niño de Guzmán; Yang Song; Pablo Alonso-Coello; Carlos Canelo-Aybar; Luciana Neamtiu; Elena Parmelli; Javier Pérez-Bracchiglione; Montserrat Rabassa; David Rigau; Zuleika Saz Parkinson; Iván Solà; Adrián Vásquez-Mejía; Ignacio Ricci-Cabello Journal: Breast Cancer Res Treat Date: 2020-05-06 Impact factor: 4.872